Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603900 | 0.86 | IDO1 (0.39) | CA1CA2IDO1NPC1POLB | |
| SCHEMBL5983235 | 0.76 | NPC1 (0.48) | CA1CA2NPC1POLBMEN1 | |
| SCHEMBL9812331 | 0.74 | IDO1 (0.47) | CA1CA2IDO1APPNPC1 | |
| SCHEMBL7227231 | 0.74 | POLB (0.53) | CA1CA2NPC1POLBMEN1 | |
| SCHEMBL12883526 | 0.74 | TSHR (0.48) | CA1CA2TRPV1HDAC8NPC1 | |
| SCHEMBL2341420 | 0.74 | MAPT (0.42) | APPNPC1POLBL3MBTL1MEN1 | |
| SCHEMBL12233464 | 0.74 | POLB (0.53) | CA1CA2NPC1POLBMEN1 | |
| SCHEMBL8743932 | 0.74 | IDO1 (0.33) | CA1CA2IDO1NPC1POLB | |
| SCHEMBL1011188 | 0.74 | ALDH1A1 (0.44) | ABCC9KCNJ11NPC1POLBMEN1 | |
| SCHEMBL1709085 | 0.73 | NPC1 (0.46) | NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912529-B | Method for synthesizing indole compounds by catalyzing N-aryl amide compounds and vinylene carbonate with ruthenium | 成都大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-113912529-A | Method for synthesizing indole compound by catalyzing N-aryl amide compound and vinylene carbonate with ruthenium | 成都大学 | 2022-01-11 | — | — | CN | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180071252-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9844535-B2 | SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-9844535-B2 | SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160374988-A1 | SHP2 INHIBITORS AND METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9522881-B2 | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160102054-A1 | HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-04-14 | — | — | US | disclosed |
| US-7560565-B2 | Method for preparing derivatives of 3-hydroxypicolinic acid | BAYER CROPSCIENCE SA (FR) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071252-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | PTPRJ, PTPRCAP, PTPRC | CA1 3558/4885CA2 1518/4885ABCC9 4438/4885 |
| US-20160102054-A1 | HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) | SRC, PTPRCAP, PTPRJ | CA1 2974/4885CA2 1654/4885ABCC9 4684/4885 |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | CA1 2363/4885CA2 926/4885ABCC9 1076/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | CA1 2363/4885CA2 926/4885ABCC9 1076/4885 |
| US-20160374988-A1 | SHP2 INHIBITORS AND METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | PTPRJ, PTPRCAP, PTPN2 | CA1 3495/4885CA2 1672/4885ABCC9 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.